Executive Board Partner

AIRA Sciences Inc. (Sierra Medical Ltd. UK, trading as AIRA Sciences) is a healthcare technology company focused on improving access to earlier disease detection through infrared spectroscopy and artificial intelligence.

The company operates in an area of growing national importance.

According to the American Cancer Society, approximately 12.8 million Americans are eligible for annual lung cancer screening, yet only 18.7% are currently up to date with screening recommendations. Researchers estimate that more than 62,000 lung cancer deaths could be prevented over five years if all eligible individuals were screened.

Founded as Sierra Medical, the company has spent more than a decade developing the scientific, clinical and operational foundations required to support earlier disease detection.

In June 2026, the company launched as AIRA Sciences and appointed Dr. Scott Tackett as Chief Executive Officer and President.

Dr. Tackett joins AIRA Sciences following more than a decade at Intuitive Surgical, where he led Global Market Access, Value & Economics initiatives during a period in which the company grew from approximately $2 billion to $11 billion in annual revenue. His doctoral research focused on lung cancer screening programmes and hospital effectiveness.

Founder Dr. Liberty Foreman continues with the company as Chief Innovation Officer and Chair of the Board, leading long-term platform, product and scientific strategy.

The wider leadership team remains in place, including CFO Robert Denton, whilst clinical programmes, regulatory initiatives and product development activities continue as planned.

As part of this next chapter, AIRA Sciences is selectively expanding its Executive Board Partner programme.

THE OPPORTUNITY

AIRA Sciences is forming a selective group of Executive Board Partners aligned with the company's commercialisation activities and long-term development.

This role is distinct from formal Board membership, yet operates in close strategic alignment with governance and ownership.

Executive Board Partners engage as senior operators, executives and capital allocators who can contribute strategic insight during a period of commercial growth and organisational expansion.

Participation is curated and intentionally limited.

WHY AIRA SCIENCES

The company has spent more than a decade developing the scientific, clinical and operational foundations required to support commercial deployment.

Today, several important developments are occurring simultaneously:

• Growing national focus on early cancer detection
• Increased awareness of the lung cancer screening gap
• Active clinical validation programmes
• Established commercial infrastructure
• Expansion of US operations
• New executive leadership focused on commercial scale
• Preparations for future fundraising and growth initiatives

Executive Board Partners participate during a period defined by implementation, commercialisation and organisational growth.

ROLE OF EXECUTIVE BOARD PARTNERS

Executive Board Partners contribute through:

• Strategic dialogue around commercialisation and market adoption
• Healthcare market access and reimbursement expertise
• Scaling regulated healthcare businesses
• Strategic partnerships and industry relationships
• Capital-aligned ownership participation
• Long-term company development
• Governance-level perspective and executive leadership experience

Engagement is strategic and periodic, not operational.

COMPENSATION & ALIGNMENT

This is an equity-based position aligned with ownership participation in the company.

Executive Board Partner participation is structured for individuals who believe strategic contribution and ownership alignment should operate together.

This is not a cash-compensated position.

IDEAL PROFILE

We are seeking senior executives with 10+ years of leadership experience across one or more of the following areas:

• Healthcare systems, diagnostics or laboratory services
• Medical technology and regulated healthcare businesses
• Healthcare commercialisation and market access
• Life sciences and healthcare innovation
• Enterprise technology and data-driven platforms
• Executive leadership roles including CEO, COO, CTO, President or Business Unit Leader
• Venture capital, private equity or principal investment activities
• Board, governance or strategic oversight experience

We are particularly interested in individuals who:

• Have scaled organisations through periods of growth
• Understand regulated healthcare environments
• Bring strategic networks and industry relationships
• Have experience navigating commercial adoption challenges
• Engage as long-term owners rather than external advisers
  

The company is no longer solely focused on technology development and validation.

The focus is increasingly centred on implementation, commercialisation, adoption and scale.

With clinical validation activities progressing, commercial infrastructure established, and experienced leadership in place, AIRA Sciences is entering a period of execution and growth.

Executive Board expansion at this stage offers participation during a defined commercialisation inflection point.

WHAT HAS NOT CHANGED

While the company has launched as AIRA Sciences and appointed a new CEO, several important elements remain unchanged:

• Dr. Liberty Foreman remains Founder, Chief Innovation Officer and Chair of the Board
• The senior leadership team remains in place
• Clinical validation activities continue
• AIR-DS Lung remains the lead programme
• The broader platform roadmap continues
• The company's mission remains focused on improving access to earlier disease detection

EQUAL OPPORTUNITY COMMITMENT

AIRA Sciences is committed to building a diverse, inclusive and representative leadership community.

We welcome applicants from all backgrounds and believe diverse perspectives strengthen decision-making, governance and long-term company development.